Coherus Oncology Inc(CHRS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD

Q: What kind of company is CHRS?

CHRS belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of CHRS?

The market cap of CHRS is approximately $139M, ranking 4,284 within its sector.

Q: What is the 52-week high and low for CHRS?

CHRS has recorded a 52-week high of $2.62 and a low of $0.94.

CHRS

Coherus Oncology Inc

At close Oct 29 at 4:00 PM ET (Korea 10/30 05:00)

$0.90

-0.26 ▼ -22.55%

Oct 30 at 7:00 AM ET (Korea 10/30 20:00)

$0.90

+0.00 +0.04%

Full metrics table

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-1.02	Insider Own ⓘ	25.3%	Shs Outstand ⓘ	154.5M	Perf Week ⓘ	-14.44%
Market Cap ⓘ	0.14B	Forward P/E ⓘ	-	EPS next Y ⓘ	8.74%	Insider Trans ⓘ	-	Shs Float ⓘ	115.4M	Perf Month ⓘ	-25.75%
Enterprise Value ⓘ	0.09B	PEG ⓘ	-	EPS next Q ⓘ	-0.22	Inst Own ⓘ	34.31%	Short Float ⓘ	10.79%	Perf Quarter ⓘ	-36.28%
Income ⓘ	-0.13B	P/S ⓘ	2.72	EPS this Y ⓘ	43.78%	Inst Trans ⓘ	-1.4%	Short Ratio ⓘ	9.65	Perf Half Y ⓘ	-49.39%
Sales ⓘ	0.05B	P/B ⓘ	2.28	EPS next 5Y ⓘ	32.84%	ROA ⓘ	-51.1%	Short Interest ⓘ	12.45M	Perf YTD ⓘ	-36.73%
Book/sh ⓘ	0.39	P/C ⓘ	1.32	EPS past 3/5Y ⓘ	27.14% -	ROE ⓘ	-178.39%	52W High ⓘ	-65.65% ($2.62)	Perf Year ⓘ	-48.07%
Cash/sh ⓘ	0.68	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-41.54% -38.41%	ROIC ⓘ	-115.55%	52W Low ⓘ	-4.43% ($0.94)	Perf 3Y ⓘ	-65.97%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	25.83%	Gross Margin ⓘ	61.86%	Volatility(W/M) ⓘ	13.87% 8.52%	Perf 5Y ⓘ	-94.63%
Dividend TTM ⓘ	-	EV/Sales ⓘ	1.72	Sales Y/Y TTM ⓘ	-64.32%	Oper. Margin ⓘ	-307.43%	ATR (14) ⓘ	0.09	Perf 10Y ⓘ	-96.87%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	1.7	EPS Q/Q ⓘ	63.16%	Profit Margin ⓘ	-256.49%	RSI (14) ⓘ	37.38	Recom ⓘ	1.33
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.77	Sales Q/Q ⓘ	39.53%	SMA20 ⓘ	-13.81% ($1.04)	Beta ⓘ	0.99	Target Price ⓘ	$7.75
Payout ⓘ	-	Debt/Eq ⓘ	0.89	Earnings ⓘ	2026/11/9	SMA50 ⓘ	-25.64% ($1.21)	Rel Volume ⓘ	4.75	Prev Close ⓘ	$1.16
Employees ⓘ	147	LT Debt/Eq ⓘ	0.86	EPS/Sales Surpr. ⓘ	12% -0.69%	SMA200 ⓘ	-41.45% ($1.54)	Avg Volume(3M) ⓘ	1.29M	Price ⓘ	$0.9
IPO ⓘ	2014/11/6	Option/Short ⓘ	Yes/Yes			Trades ⓘ	5291	Volume ⓘ	6,137,009	Change ⓘ	-22.55%

Company

CHRSCoherus Oncology Inc | NASD | Biotechnology Deep dive

🧬 This is a U.S. biotech company focused on immuno-oncology cancer treatment. The company originated from a biosimilars business, but after divesting its UDENYCA franchise, it has restructured its operations around its nasopharyngeal cancer treatment LOQTORZI (toripalimab) and a new immuno-oncology pipeline. It is headquartered in the United States.

Quote

Over the past 1 year, on the lower side

66% below its 1-year high.

Now $0.90

52w low$0.9452w high$2.62

52W Range0%

6,137,009

Traded more than usual. That is 475% of its average volume.

Upcoming events

Next earnings report: November 9

10 days to go.

Earnings dateNovember 9

Overall · average, with some caution

We judged 7 of the 8 questions below. 2 rate excellent and 3 need caution.

Not applicable: dividends.

Is it profitable? C

CHRS has a sound balance sheet but weak earning power

Losses exceed revenue. The business is barely earning yet.

61.86%

#63 of 131 in Biotechnology Micro-cap

1.77x

#265 of 587 in Biotechnology

1.7x

#265 of 586 in Biotechnology

Center line = peer midpoint

0.89x

-307.43%

-256.49%

-178.39%

-51.1%

-115.55%

25 June

25 September

26 March

26 June

Revenue Operating income $-32.3M Net income $-20.6M

Tap to view numbers

Is it growing? A

Earnings are growing steadily

Earnings are expected to grow by +43.8% this year.

Tap to view numbers

Is it attractive at this price? A

Relative to sales, it looks cheap

Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $272. Peers typically go for $1,089. Compared with its own 2-year average, it is 50% cheaper now.